Trial · NCT02616393
Adverse events428
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 428
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Cohort A - Brain Metastases | 10 | 13 | |
| other | Diarrhea | Gastrointestinal disorders | Cohort B - Leptomeningeal Metastases | 14 | 20 | |
| other | Diarrhea | Gastrointestinal disorders | Cohort C - Brain Metastases at Initial Presentation | 0 | 3 | |
| other | Diarrhea | Gastrointestinal disorders | All Subjects (Cohorts A+B+C) | 24 | 36 | |
| other | Fatigue | General disorders | Cohort A - Brain Metastases | 5 | 13 | |
| other | Fatigue | General disorders | Cohort B - Leptomeningeal Metastases | 8 | 20 | |
| other | Fatigue | General disorders | Cohort C - Brain Metastases at Initial Presentation | 3 | 3 | |
| other | Fatigue | General disorders | All Subjects (Cohorts A+B+C) | 16 | 36 | |
| other | QT Prolongation | Investigations | Cohort A - Brain Metastases | 5 | 13 | |
| other | QT Prolongation | Investigations | Cohort B - Leptomeningeal Metastases | 9 | 20 | |
| other | QT Prolongation | Investigations | Cohort C - Brain Metastases at Initial Presentation | 1 | 3 | |
| other | QT Prolongation | Investigations | All Subjects (Cohorts A+B+C) | 15 | 36 | |
| other | Nausea | General disorders | Cohort A - Brain Metastases | 7 | 13 | |
| other | Nausea | General disorders | Cohort B - Leptomeningeal Metastases | 5 | 20 | |
| other | Nausea | General disorders | Cohort C - Brain Metastases at Initial Presentation | 1 | 3 | |
| other | Nausea | General disorders | All Subjects (Cohorts A+B+C) | 36 | 36 | |
| other | Rash | Skin and subcutaneous tissue disorders | Cohort A - Brain Metastases | 6 | 13 | |
| other | Rash | Skin and subcutaneous tissue disorders | Cohort B - Leptomeningeal Metastases | 2 | 20 | |
| other | Rash | Skin and subcutaneous tissue disorders | Cohort C - Brain Metastases at Initial Presentation | 3 | 3 | |
| other | Rash | Skin and subcutaneous tissue disorders | All Subjects (Cohorts A+B+C) | 11 | 36 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02616393/events